# Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

> **NCT05610319** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **McMaster University** · enrollment: 446 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT05610319
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610319, "Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05610319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*